CV Sciences (CVSI) Free Cash Flow Growth (1y) (2012 - 2026)
CV Sciences (CVSI) Free Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -94.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -94.54% |
| Mar 31, 2026 | 180.99% |
| Dec 31, 2025 | -69.78% |
| Sep 30, 2025 | -159.84% |
| Jun 30, 2025 | 517.54% |
| Mar 31, 2025 | 76.64% |
| Dec 31, 2024 | -59.65% |
| Sep 30, 2024 | -542.11% |
| Jun 30, 2024 | -104.04% |
| Mar 31, 2024 | -153.13% |
| Dec 31, 2023 | -154.29% |
| Sep 30, 2023 | 96.53% |
| Jun 30, 2023 | 220.70% |
| Mar 31, 2023 | 357.26% |
| Dec 31, 2022 | 118.04% |
| Sep 30, 2022 | 65.11% |
| Jun 30, 2022 | 61.85% |
| Mar 31, 2022 | 78.02% |
| Dec 31, 2021 | 49.08% |
| Sep 30, 2021 | -7.32% |